Compares a low-field MRI scanner with standard MRI for prostate cancer screening
Tests a low-field MRI scanner against standard MRI to screen for prostate cancer.
Plain-language title generated from the registry record
Registry title: Accurate Prostate Cancer Following Using Low-Field MRI (Low-PRISM)
Key facts
- Where
- Lausanne, SwitzerlandSee the site
Where in Switzerland
- Lausanne University HospitalLausanne, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Lausanne Hospitals
- Trial code
- NCT06482489
- Record updated
- 30 October 2026
- Original description
This study compares the effectiveness of low-field MRI (0.55T) with high-field MRI (3T) in prostate cancer screening and image quality. It consists of three phases: optimizing the low-field MRI protocol with healthy volunteers, evaluating image quality in patients with metallic artifacts (like hip prostheses), and assessing low-field MRI in patients with suspicious prostate lesions found on high-field MRI.Read full original descriptionShow less
Comparing Prostate Cancer Screening Between Standardized 3T MRI Screening Protocol and Low-Field MRI in a Prospective Study
This study compares the effectiveness of low-field MRI (0.55T) with high-field MRI (3T) in prostate cancer screening and image quality. It consists of three phases: optimizing the low-field MRI protocol with healthy volunteers, evaluating image quality in patients with metallic artifacts (like hip prostheses), and assessing low-field MRI in patients with suspicious prostate lesions found on high-field MRI.
Inclusion: Work Package1 (WP): 0.55T MRI Protocol Development; Healthy male volunteers aged 18 and above; Agree to be contacted for incidental findings; Signed informed consent; WP2: 0.55T Prostate MRI with patients with metallic implant(s); Adult men (≥18 y.o) with 3T MRI reported as sub-diagnostic due to metallic implants; Signed informed Consent; WP3: 0.55T Prostate MRI with patients with suspicious lesion(s); Adult men (≥18 y.o); PI-RADS 4/5 lesions detected on 3T MRI, schedules for targeted biopsy; Signed informed consent.
Exclusion: MR Contraindications as listed in the MR Safety Screening form; WP2: 0.55T Prostate MRI with patients with metallic implant(s); Individuals with a history of prostate cancer; Any condition making the patient unsuitable for the study; Individuals with a history of prostate cancer; Any condition making the patient unsuitable for the study; WP1: 0.55T MRI Protocol Development; Contraindications as per MD instructions; Refusal to be notified in case of incidental finding on the examination; WP3: 0.55T Prostate MRI with patients with suspicious lesion(s); Contraindications as per MD instructions; Refusal to be notified in case of incidental finding on the examination.